Advances in Melanoma: From Pathogenesis to Personalized Therapy
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Dermato-Oncology".
Deadline for manuscript submissions: 14 November 2025 | Viewed by 177
Special Issue Editor
Interests: skin cancer; prostate cancer; lung cancer; CNS cancer; epidemiology; outcome research; merkel cell carcinoma; database
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue will focus on the latest clinical advancements in melanoma management, emphasizing personalized treatment strategies and real-world applications. Contributions will highlight the evolving role of targeted therapies (BRAF/MEK inhibitors) and immunotherapy (PD-1/CTLA-4 blockade) in improving survival outcomes in advanced melanoma. Key discussions in this area include predictive biomarkers for treatment selection, strategies to overcome therapy resistance, and the integration of novel combination therapies into clinical practice. This Special Issue will also explore emerging diagnostic tools, such as liquid biopsies and imaging advancements, for early detection and monitoring. Additionally, real-world data on treatment sequencing, adjuvant therapy optimization, and long-term survivorship will be addressed. By bridging translational research and clinical practice, this Special Issue will provide actionable insights for oncologists to utilize in enhancing melanoma care. To encompass the entire journey of melanoma care, the latest developments in palliative care, including spiritual care, will be discussed.
Dr. Patricia Tai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- clinical management
- targeted therapy
- immunotherapy
- BRAF inhibitors
- PD-1 blockade
- predictive biomarkers
- treatment resistance
- combination therapy
- liquid biopsy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
